Sec Form 4 Filing - Capital Royalty L.P. @ Zyla Life Sciences - 2019-06-28

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Capital Royalty L.P. 2. Issuer Name and Ticker or Trading Symbol Zyla Life Sciences [ ZCOR] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director X __ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) 1000 MAIN ST., SUITE 2500 3. Date of Earliest Transaction (MM/DD/YY) 06/28/2019 (Street) HOUSTON, TX77002 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) _____ Form filed by One Reporting Person __ X __ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 06/28/2019 J 4,586,874 D 0 I By Iroko Properties Inc. ( 1 ) Common Stock 06/28/2019 J 4,586,874 A 4,586,874 I By Loan Security Holdings I LLC ( 1 )

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Warrants $ 0.0001 06/28/2019 J 2,436,459 ( 2 ) ( 2 ) Common Stock 2,436,459 ( 2 ) 0 I By Iroko Properties Inc. ( 1 ) Warrants $ 0.0001 06/28/2019 J 2,436,459 ( 2 ) ( 2 ) Common Stock 2,436,459 ( 2 ) 2,436,459 I By Loan Security Holdings I LLC ( 1 )

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Capital Royalty L.P. 1000 MAIN ST. SUITE 2500 HOUSTON, TX77002 X Iroko Pharmaceuticals Inc. 150 ROUSE BOULEVARD PHILADELPHIA, PA19112 X Iroko Properties Inc. 150 ROUSE BOULEVARD PHILADELPHIA, PA19112 X CRG Partners III (Cayman) Lev AIV I L.P. 1000 MAIN ST. SUITE 2500 HOUSTON, TX77002 X CRG Partners III (Cayman) Unlev AIV I L.P. 1000 MAIN ST. SUITE 2500 HOUSTON, TX77002 X CRG Partners III L.P. 1000 MAIN ST. SUITE 2500 HOUSTON, TX77002 X Loan Security Holdings I LLC 1000 MAIN ST. SUITE 2500 HOUSTON, TX77002 X CRG Partners III - Parallel Fund B (Cayman) L.P. 1000 MAIN ST. SUITE 2500 HOUSTON, TX77002 X CRG Partners III - Parallel Fund (A) L.P. 1000 MAIN ST. SUITE 2500 HOUSTON, TX77002 X Signatures /s/ Nathan D. Hukill, authorized signatory for CR Group L.P. and each of the CRG Entities 07/03/2019 Signature of Reporting Person Date /s/ Mark Murphy, authorized signatory for each of Iroko Pharmaceuticals Inc. and Iroko Properties Inc. 07/03/2019 Signature of Reporting Person Date /s/ Andrei Dorenbaum, authorized signatory for Loan Security Holdings I LLC 07/03/2019 Signature of Reporting Person Date

Explanation of Responses:

( 1 )The shares of Common Stock (the "Shares") and the Warrants were acquired by Loan Security Holdings I LLC, a wholly owned LLC held by CRG Partners III - Parallel Fund "A" LP, CRG Partners III - Parallel Fund "B" (Cayman) L.P., CRG Partners III (Cayman) Lev AIV I L.P., CRG Partners III (Cayman) Unlev AIV I L.P., and CRG Partners III L.P. (collectively, the "CRG Entities"), as a result of foreclosure sale of certain assets of Iroko Pharmaceuticals Inc. and its subsidiaries on June 28, 2019. CRG Entities collectively hold all of the issued and outstanding shares of Loan Security Holdings I LLC. CR Group L.P. may be deemed to beneficially own the Shares and the Warrants by virtue of its position as the investment manager for the CRG Entities. This Form 4 is filed jointly by Iroko Pharmaceuticals Inc., Iroko Properties Inc., CR Group L.P. and each of the CRG Entities.This transaction is exempt under Rule 16a-13 as a change in form of beneficial ownership. ( 2 )Pursuant to the terms of the Warrants, Loan Security Holdings I LLC has the right to acquire up to 2,436,459 additional shares of Common Stock, provided however that, for a period of eighteen (18) months following the date of the issuance of the Warrants, Loan Security Holdings I LLC's right to exercise the Warrants is restricted so that it does not hold more than 49% of the issued and outstanding shares of Common Stock of the Issuer. The Warrants do not have an expiration date.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.